Fertility and Ovarian Reserve Function in the Patient With Inflammatory Bowel Disease

NCT ID: NCT03269916

Last Updated: 2017-09-01

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

80 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-05-01

Study Completion Date

2018-08-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

ECCO consensus, the fertility would decline in activity inflammatory bowel disease(IBD), because of anus lesions and pelvic abscess, or who underwent surgery, especially in patients with ileal pouch anal anastomosis (IPAA) storage.The study on fertility in inflammatory bowel disease were almost epidemiological investigation, the lack of objective evaluation of fertility, and controversial.This study will explore the fertility, ovarian reserve function and the pregnancy outcomes in patients with IBD.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Fertility Disorders Ovarian Reserve Function Pregnancy Outcomes

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

IBD patients

IBD patients, 17-40 years old, female

Group Type EXPERIMENTAL

Anti Mueller hormone

Intervention Type OTHER

used to assess ovarian reserve parameters

Estrogen

Intervention Type OTHER

used to assess ovarian reserve parameters

Follicle-Stimulating Hormone

Intervention Type OTHER

used to assess ovarian reserve parameters

Antral alveolar cell count

Intervention Type OTHER

used to assess ovarian reserve parameters

healthy control

17-40 years old , female, without any gynecological disease

Group Type OTHER

Anti Mueller hormone

Intervention Type OTHER

used to assess ovarian reserve parameters

Estrogen

Intervention Type OTHER

used to assess ovarian reserve parameters

Follicle-Stimulating Hormone

Intervention Type OTHER

used to assess ovarian reserve parameters

Antral alveolar cell count

Intervention Type OTHER

used to assess ovarian reserve parameters

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Anti Mueller hormone

used to assess ovarian reserve parameters

Intervention Type OTHER

Estrogen

used to assess ovarian reserve parameters

Intervention Type OTHER

Follicle-Stimulating Hormone

used to assess ovarian reserve parameters

Intervention Type OTHER

Antral alveolar cell count

used to assess ovarian reserve parameters

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Inflammatory bowel disease
2. 17-40 years old
3. female

Exclusion Criteria

1. in pregnancy or lactation
2. a drug that has been or is being used known to affect ovarian function, such as cyclophosphamide
3. reproductive system diseases unrelated to disease or treatment of inflammatory bowel disease, such as hysterectomy, pelvic radiotherapy after surgery, after ovariectomy, polycystic ovary syndrome, endometriosis, ovarian granulosa cell tumor
4. other endocrine diseases, such as prolactin, hyperthyroidism, lead to endocrine disorders;
5. malignant tumor
Minimum Eligible Age

17 Years

Maximum Eligible Age

40 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Sixth Affiliated Hospital, Sun Yat-sen University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

pengxiang

Attending doctor

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Min Zhi, PHD

Role: STUDY_CHAIR

The Sixth Affiliated Hospital of Zhongshan University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

The Sixth Affiliated Hospital of Zhongshan University

Guangzhou, Guangdong, China

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

China

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

xiang peng, MM

Role: CONTACT

18302076916

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

xiang peng, MM

Role: primary

18302076916

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

SixthSunYetSen

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.